Enterprise Value to EBITDA Ratio: Revolution Medicines (RVMD)
Revolution Medicines develops unique targeted therapies to combat resistant forms of oncological diseases. The EV/EBITDA ratio of this capital-intensive business reflects the company's current valuation dynamics, where the 0.00 mark records this metric. The development of new molecules relies on external contractors, while drug synthesis is distributed across various laboratories to minimize operational risks.
Comprehensive metric breakdowns and analytics for Revolution Medicines, Inc. (RVMD)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
RVMD - Company Net Income|Future Profit Revolution Medicines|RVMD - P/E Multiple|Projected Price to Earnings Revolution Medicines|RVMD - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple RevMed|RVMD - Operating income before deduction of amortization|Earnings per share for the last twelve months Revolution Medicines|RVMD - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months revmed.com|RVMD - Earnings per share growth this year|Expected earnings per share growth for next year Revolution Medicines
- company sales and revenue statistics:
Initial company analysis:Revolution Medicines (RVMD)
This indicator compares the total value of assets and liabilities with operating profit, allowing for an assessment of the business's real value regardless of tax burden and debt structure. By analyzing the EV/EBITDA dynamics of this capital-intensive company, an investor can see how the outsourcing strategy for clinical trials and drug synthesis optimizes costs, reduces dependency risks on specific contractors, and influences the fundamental attractiveness of Revolution Medicines (RVMD).
Who Revolution Medicines competes with
BeiGene Oncology - Enterprise Value to EBITDA Ratio|HALO - Enterprise Value to EBITDA Ratio|AAPG: Enterprise Value to EBITDA Ratio|CGON - EV/EBITDA Multiple|UroGen (URGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Bicara Bio - Business Value to Operating Income Before Depreciation|PSNL (Personalis Inc) - EV/EBITDA Multiple|Company Value to EBITDA Erasca, Inc. ERAS|EV/EBITDA Multiple DCTH|YMAB - Company Value to EBITDA|Aura Biosciences Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Candel Therapeutics CADL|accuray.com - EV/EBITDA Multiple|SLS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACTU (actuatetherapeutics.com) - Enterprise Value to EBITDA Ratio|CTOR - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tuhurabio.com|EV/EBITDA Multiple Protara Tx|Enterprise Value to EBITDA Ratio FATE (Fate Therapeutics Corp)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Champions Oncology (CSBR) - Company Value to EBITDA|XBiotech - EV/EBITDA Multiple|CEL-SCI (CVM) - Enterprise Value to EBITDA Ratio|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|radiopharmtheranostics.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|Company Value to EBITDA Adlai Nortye Ltd. ANL|EV/EBITDA Multiple VERU|TPST - Company Value to EBITDA|EV/EBITDA Multiple XLO (Xilio Therapeutics)|RENB - Enterprise Value to EBITDA Ratio|muraloncology.com - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|OKUR: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Ltd)|CRIS (curis.com) - EV/EBITDA Multiple|Apollomics, Inc. (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (Advanced Biomed) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex Inc)|calidibio.com (CLDI) - Company Value to EBITDA|sunshinebiopharma.com - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Purple Biotech Ltd.|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeOne Medicines (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|iCAD Inc. - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple
